🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Sagimet Biosciences’ fourth quarter and full year 2023 financial results and corporate updates are now available: ir.sagimet.com/news-releases/…

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors. Learn more here: ir.sagimet.com/news-releases/…

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer. Learn more here: ir.sagimet.com/news-releases/…

Sagimet Biosciences’ first quarter 2024 financial results and corporate updates are now available: ir.sagimet.com/news-releases/… #biotech #NASH #denifanstat #FASN #FASCINATE2 $SGMT

Join @Sagimet ($SGMT) for a virtual investor and analyst day or a virtual investor and analyst day on Thurs. May 23 at 1:00pm ET with Scott L. Friedman, MD who will discuss the current treatment landscape for patients with #MASH. Register: lifescievents.com/event/sagimet/

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 Press Release: ir.sagimet.com/news-releases/… Presentation: sagimet.com/wp-content/upl…

Join @Sagimet ($SGMT) for a conference call & webcast on Thurs June 13 at 12:30pm ET with Rohit Loomba, M.D., M.H.Sc., to discuss positive data from FASCINATE-2 Phase 2b clinical trial of denifanstat in biopsy-confirmed MASH patients: ir.sagimet.com/events/event-d…

Today we reported our 2nd quarter 2024 financial results and provided a corporate update. Highlights included the full Phase 2b FASCINATE-2 clinical trial results presented at #EASL for our lead program, denifanstat in MASH. ir.sagimet.com/news-releases/… #MASH #FASN #FASCINATE2

Join Sagimet Biosciences ($SGMT) for a fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024. A webcast will be available in the Investors & Media section of Sagimet’s website at sagimet.com.

Sagimet Biosciences ($SGMT) will have an oral presentation highlighting denifanstat’s anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis ($MASH) at the 8th Annual MASH Drug Development Summit on September 26, 2024. Learn more here: bit.ly/3XLMmVn

Today, we announced that the U.S. FDA has granted Breakthrough Therapy designation to our lead product candidate, denifanstat, for treatment of #MASH. Learn more here: ir.sagimet.com/news-releases/…

Sagimet Biosciences announces publication of phase 2b FASCINATE-2 data of #FASN inhibitor denifanstat in biopsy-confirmed F2/F3 #MASH in The Lancet Gastroenterology & Hepatology (The Lancet Gastroenterology & Hepatology). Read more: ir.sagimet.com/news-releases/…

We’ve successfully completed end-of-phase 2 FDA interactions for development of denifanstat in MASH. Read more: ir.sagimet.com/news-releases/… #MASH #MASLD #LiverTwitter #ClinicalTrials #Biopharma

Recently, at AASLD - The Liver Meeting®, CEO David Happel was interviewed by BiotechTV Contributor Brian Orelli. Watch the full video here: x.com/BiotechTVHQ/st…

Sagimet Biosciences to present on denifanstat’s effect on triglycerides and LDL-cholesterol in advanced fibrosis patients at the Keystone Symposia on #MASH Pathogenesis and Therapeutic Approaches on February 26, 2025, at 3:00 PM MST in Banff, Canada. #SGMT #ClinicalTrials #Biopharma

Today we reported our full year 2024 financial results and provided a corporate update. Highlights included Breakthrough Therapy designation for denifanstat in MASH and IND clearance for TVB-3567 for the treatment of acne. To learn more, read ir.sagimet.com/news-releases/… #MASH #FASN

Join Sagimet Biosciences $SGMT for a virtual KOL event on May 29 at 1pm ET with Dr. Loomba, who will discuss the potential for developing a combination of denifanstat and resmetirom to treat advanced metabolic dysfunction-associated steatohepatitis (MASH). Register: lifescievents.com/event/sagimet-…

Sagimet is pleased to announce that denifanstat met all primary and secondary endpoints vs. placebo in a Phase 3 #ClinicalTrial for moderate to severe #Acne conducted by our partner for China, Ascletis. Read more: ir.sagimet.com/news-releases/…

Join Sagimet Biosciences $SGMT for a virtual KOL event on June 16 at 2pm ET with Dr. Bhatia to review positive efficacy and tolerability results from Ascletis’ Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris in China Register: lifescievents.com/event/hfu4ms9s…